Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a.

Raymond HuppertsJoost J F M SmoldersReinhold ViethTrygve HolmøyKurt MarhardtMyriam SchluepJoep KillesteinFrederik BarkhofManolo BeelkeLuigi M E Grimaldinull null

Published in: Neurology (2019)

This study provides Class II evidence that for patients with RRMS treated with SC IFN-β-1a, 48 weeks of cholecalciferol supplementation did not promote NEDA-3 status.

Keyphrases

high dose
dendritic cells
low dose
physical activity
newly diagnosed